Aspire Biopharma Holdings (ASBP) Non-Current Deffered Revenue (2022 - 2024)
Aspire Biopharma Holdings (ASBP) posted quarterly Non-Current Deffered Revenue of $5.0 million for Q4 2024, up 566.67% quarter-over-quarter from $750000.0 in Q3 2023.
Aspire Biopharma Holdings (ASBP) Non-Current Deffered Revenue (2022 - 2024) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Non-Current Deffered Revenue for 3 consecutive years, with $5.0 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Non-Current Deffered Revenue changed N/A year-over-year to $5.0 million; the TTM figure through Dec 2024 stood at $5.0 million (changed N/A YoY), while the FY2024 annual figure was $5.0 million, changed N/A from the prior year.
- Non-Current Deffered Revenue improved to $5.0 million in Q4 2024 per ASBP's latest filing, from $750000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $5.0 million in Q1 2022 and bottomed at $750000.0 in Q2 2022.
- Historically, Non-Current Deffered Revenue has averaged $2.3 million across 3 years, with a median of $750000.0 in 2022.
- On a YoY basis, Non-Current Deffered Revenue climbed as much as 0.0% in 2023 and fell as far as 85.0% in 2023.
- Aspire Biopharma Holdings' Non-Current Deffered Revenue stood at $750000.0 in 2022, then changed by 0.0% to $750000.0 in 2023, then surged by 566.67% to $5.0 million in 2024.
- Business Quant data shows ASBP's Non-Current Deffered Revenue at $5.0 million in Q4 2024, $750000.0 in Q3 2023, and $750000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 5.00 Mn |
| Sep 30, 2023 | 750,000.00 |
| Jun 30, 2023 | 750,000.00 |
| Mar 31, 2023 | 750,000.00 |
| Dec 31, 2022 | 750,000.00 |
| Sep 30, 2022 | 5.00 Mn |
| Jun 30, 2022 | 750,000.00 |
| Mar 31, 2022 | 5.00 Mn |